| Expression pattern: |
UN |
| Associated gene: |
TFII-I, STAT1, CXCL10, CXCL11 |
| Associated microRNA: |
- |
| Biological function: |
Promotes tumor progression and reduces CD8+ T cell infiltration in vivo; compromises anti-PD-1 therapy response. |
| Molecular mechanism: |
Binds TFII-I and disrupts TFII-I/STAT1 interaction, reducing STAT1 phosphorylation and downregulating CXCL10/CXCL11 in LLC cells. |
| Biological pathway or process: |
immune regulation (inhibits); drug resistance (promotes) |
| Detected method: |
Q
|
| Validation methods: |
FISH / smFISH; RNA Pull-Down; RIP (RNA Immunoprecipitation); RT-qPCR; Co-IP; Western Blot; Transfection; In Vivo Animal Model; IHC (Immunohistochemistry); Flow Cytometry(Non-apoptosis/cycle) |
| Clinical significance: |
- |
| Description: |
In the mouse LLC syngeneic model, nuclear circFndc3b binds TFII-I and interferes with TFII-I/STAT1 signaling, suppressing CXCL10/CXCL11 and limiting CD8+ T-cell infiltration. This promotes tumor growth and reduces response to anti-PD-1 therapy. |
| Confidence score: |
0.729 |